Empagliflozin benefits in patients with heart failure and preserved ejection fraction

Autores da FMUP

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• Anker, SD
• Butler, J
• Usman, MS
• Filippatos, G
• Bocchi, E
• Böhm, M
• Brunner-La Rocca, HP
• Choi, DJ
• Chopra, V
• Chuquiure, E
• Giannetti, N
• Gomez-Mesa, JE
• Janssens, S
• Januzzi, JL
• González-Juanatey, JR
• Merkely, B
• Nicholls, SJ
• Perrone, SV
• Piña, IL
• Ponikowski, P
• Senni, M
• Sim, D
• Spinar, J
• Squire, I
• Taddei, S
• Tsutsui, H
• Verma, S
• Vinereanu, D
• Zhang, J
• Iwata, T
• Schnee, JM
• Brueckmann, M
• Pocock, SJ
• Zannad, F

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF >= 50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.